Authors
Latest:
Cilta-Cel Yields High Response Rates in R/R Multiple Myeloma: Saad Z. Usmani, MD, MBA, FACPThe director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed overall response rate and stringent complete responses in the CARTITUDE-1 trial.
Latest:
Characteristics, Healthcare Utilization, and Costs of Medicare Patients Receiving CAR T-Cell TherapyKarl M. Kilgore, PhD, senior research scientist, Avalere Health, discusses real-world data regarding Medicare patients with non-Hodgkin lymphoma receiving CAR T-cell therapy.
Latest:
Andrew J. Cowan, MD, Discusses the Phase I Clinical Trial of GSI and BCMA CAR T-CellsThe expert explained the rationale for the phase I first-in-human clinical trial evaluating the combination of a gamma-secretase inhibitor and B-cell maturation antigen CAR T-cells in patients with heavily pretreated multiple myeloma.
Latest:
Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma CollaborationAmgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.
Latest:
Dr. Sadelain on CAR T-Cell TherapiesMichel Sadelain, MD, PhD, Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Stephen and Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center (MSK), discusses chimeric antigen receptor (CAR) t-cell therapies.
Latest:
June Provides Insight Into Managing AEs From CAR T-Cell TherapiesThough clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor T-cell therapy
Latest:
Gene Therapy for Overactive Bladder, Incontinence Shows Good Safety, EfficacyThe locally injected gene therapy product is the subject of an ongoing phase 2a clinical trial.
Latest:
KTE-X19 Safe, Efficacious as Therapy for Pediatric B-Cell ALL in ZUMA-4Results of the phase 1 portion of ZUMA-4 support continued investigation into the efficacy of KTE-X19 in pediatric patients with B-cell acute lymphoblastic leukemia.
Latest:
Dr. D’Angelo on Selecting CAR T-Cell Therapy or Transplantation in DLBCLChristopher R. D’Angelo, MD, discusses factors that determine whether CAR T-cell therapy or autologous stem cell transplant should be used in patients with relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Investigating Strategies to Treat SCD Using Gene TherapyAn expert in hematology/oncology discusses the emerging role of gene therapy to treat sickle cell disease.
Latest:
Intravitreal Gene Therapy for Wet AMDAn overview of new gene therapy options for wet AMD that are currently being explored in clinical trials.
Latest:
KRd-Autologous Stem Cell Transplant Improves PF Survival in Multiple MyelomaData from the FORTE trial were presented at the 18th International Myeloma Workshop.
Latest:
Early Intervention For Neurotoxicity Can Improve Outcomes With Cilta-Cel in Relapsed/Refractory Multiple MyelomaNeurologic adverse effect associated with CAR T-cell therapies like ciltacabtagene autoleucel can be managed without long-term lasting effects, as long as they are caught and treated promptly in patients with relapsed/refractory multiple myeloma.
Latest:
Gene Therapy May Improve Vision in XLRP, Further Research NeededSerious adverse events of reduced visual acuity and eye inflammation were observed in 2 clinical trials.
Latest:
Optogenetic Gene Therapy Restores Vision in 11 Retinitis Pigmentosa PatientsNanoscope Therapeutics Inc. expects to advance the therapy by launching a late-stage Phase 2b trial this summer with gene therapy that delivers multi-characteristic opsin to retinal cells.
Latest:
Commentary (Cohen/Vokes): Gene Therapy for Head and Neck CancersThis issue of Oncology features an excellent review of gene therapy for head and neck cancers. Lamont and colleagues have highlighted the principles of genetic intervention, the current state of available therapies, and the results of human trials in an organized and coherent manner.
Latest:
Commentary (Cohen/Vokes): Gene Therapy for Head and Neck CancersThis issue of Oncology features an excellent review of gene therapy for head and neck cancers. Lamont and colleagues have highlighted the principles of genetic intervention, the current state of available therapies, and the results of human trials in an organized and coherent manner.
Latest:
Gene Therapy for Ovarian CancerAdvances in molecular virology and biotechnology have led to the engineering of vectors that can efficiently transfer genes to target cells. Gene therapy strategies were developed along two lines: Cytotoxic approaches
Latest:
Gene Therapy for Ovarian CancerAdvances in molecular virology and biotechnology have led to the engineering of vectors that can efficiently transfer genes to target cells. Gene therapy strategies were developed along two lines: Cytotoxic approaches
Latest:
HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Therapeutic ImplicationsOverexpression by the HER2 gene plays a significant role in breast cancer pathogenesis, and the phenomenon is commonly regarded as a predictor of a poor prognosis. HER2 overexpression has been linked to sensitivity and/or resistance to hormone therapy and chemotherapeutic regimens, including CMF (cyclophosphamide, methotrexate, and fluoro-uracil) and anthracyclines. Studies of patients with advanced disease demonstrate that, despite the association of HER2 overexpression with poor prognosis, the odds of HER2-positive patients responding clinically to taxanes were greater than three times those of HER2-negative patients. Further studies in preclinical models used combination therapy for breast cancer cells that overexpress HER2, and the use of agents that interfere with HER2 function plus paclitaxel (Taxol) resulted in significant antitumor effects. [ONCOLOGY 11(Suppl):43-48, 1997]
Latest:
Gene Therapy for Head and Neck CancersDespite advances in surgery, radiotherapy, and chemotherapy, survival of patients with squamous cell carcinoma of the head and neck has not significantly improved over the past 30 years. Locally recurrent or refractory disease is particularly difficult to treat. Repeat surgical resection and/or radiotherapy are often not possible, and long-term results for salvage chemotherapy are poor. Recent advances in gene therapy have been applied to recurrent squamous cell carcinoma of the head and neck. Many of these techniques are now in clinical trials and have shown some efficacy. This article discusses the techniques employed in gene therapy and summarizes the ongoing protocols that are currently being evaluated in clinical trials. [ONCOLOGY 15(3):303-314, 2001]
Latest:
FDA Grants Crizotinib Priority Review in ROS1-Mutated Lung CancerThe targeted, oral therapy crizotinib (Xalkori), has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have c-ros oncogene 1 (ROS1)-rearranged tumors.
